RxDoctor Payments Data

Melissa Rikal

Family · Nashville, TNNPI 1417373267

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $103,348 of the $144,428 with a category attached, or 71.6%. 45 manufacturers reported payments, led by Daiichi Sankyo Inc. at 59.9% of the total. 2025 is the largest year on record at $64,644, 2.1 times the $30,944 reported in 2021. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$144,428in general payments, 2019–2025

Across 384 payments — averaging $376.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$86K
  • AstraZeneca$45K
  • Seagen Inc.$8K
  • Stemline Therapeutics Inc.$1K
  • Pfizer$1K
  • Regeneron Healthcare Solutions, Inc.$547
  • plus $2K from 39 others

What the payments were for

  • Consulting fees$4,3453%
  • Speaking & faculty fees$103,34872%
  • Travel & lodging$27,43419%
  • Food & beverage$9,2026%
  • Education$990%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,428 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$980
Medicare patients
18
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Letrozole24$778
Tamoxifen Citrate22$358
Oxycodone Hcl15$282
Gabapentin17$263
Potassium Chloride23$167

Paid to pharmacies, not to this prescriber.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →